HSPG2 and acute myeloid leukemia: Univariate analyses and multivariate analyses on OS and LFS in the whole-cohort AML patients were performed, including the expression level of HSPG2, age (≥60 vs. <60 years old), WBC (≥30 × 109/L vs. <30 × 109/L), BM blasts(≥70% vs. <70%), treatment regimen and gene mutations (mutant vs. wild-type).